Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9466
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDonnan, Geoffrey Aen
dc.contributor.authorDavis, Stephen Men
dc.contributor.authorThrift, Amanda Gen
dc.date.accessioned2015-05-15T22:34:19Z
dc.date.available2015-05-15T22:34:19Z
dc.date.issued2003-02-01en
dc.identifier.citationCurrent Opinion in Neurology; 16(1): 81-6en
dc.identifier.govdoc12544861en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9466en
dc.description.abstractElevated blood pressure is one of the most potent risk factors for first ever and recurrent stroke as well as influencing early outcome after acute stroke. There have been a number of significant randomized controlled trials which may influence management in each of these three categories.For primary prevention, the recent information from the Heart Outcomes Prevention Evaluation, Losartan Intervention for Endpoint Reduction to Hypertension, Study on Cognition and Prognosis in the Elderly and Australian National Blood Pressure Study support the view that blood pressure lowering protects against stroke regardless of baseline blood pressure level. There is some evidence that blockade of the angiotensin system may give additional protection. For secondary prevention, evidence from the Perindopril Protection against Recurrent Stroke Study shows that blood pressure lowering with perindopril based therapy reduces fatal or non-fatal stroke events, again in hypertensive or normotensive individuals. There is uncertainty about blood pressure lowering in acute stroke, although presentation of the recent Acute Candesartan Cilexetil Evaluation in Stroke Survivors trial in which there was significant protection against vascular events using candesartan suggests that further studies should be undertaken.Blood pressure lowering for primary prevention of stroke should be undertaken using a variety of therapeutic agents. For secondary stroke prevention perindopril based therapy should be used based on current evidence. Uncertainty still exists as to whether blood pressure lowering in the acute stroke setting is safe or improves outcomes.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAntihypertensive Agents.adverse effects.therapeutic useen
dc.subject.otherCerebral Infarction.drug therapy.etiologyen
dc.subject.otherHumansen
dc.subject.otherHypertension.complications.drug therapyen
dc.subject.otherPerindopril.adverse effects.therapeutic useen
dc.subject.otherRandomized Controlled Trials as Topicen
dc.subject.otherRecurrenceen
dc.subject.otherTreatment Outcomeen
dc.titleThe role of blood pressure lowering before and after stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitleCurrent opinion in neurologyen
dc.identifier.affiliationNational Stroke Research Institute, Austin & Repatriation Medical Centre, University of Melbourne, West Heidelberg, and Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australiaen
dc.identifier.doi10.1097/01.wco.0000053585.70044.2cen
dc.description.pages81-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/12544861en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.